ProSensa bags GSK deal for RNA-based Duchenne candidates
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has agreed to pay £16 million up front for exclusive global rights to ProSensa's mid-stage RNA-based therapeutic for the genetic disease Duchenne muscular dystrophy (DMD) and options to three further DMD candidates. The deal could be worth up to £428 million to the Dutch biotechnology company if all four products are successfully developed.